Rua Bioscience Limited — Capital/Financing Update 2024

Nov 24, 2024

MARKET UPDATE

==> picture [132 x 77] intentionally omitted <==

FOR PUBLIC RELEASE

NZX Limited Wellington

25 November 2024

Rua Bioscience Sales Update

E ngā iwi, ngā hapū, me ngā whānau o te motu, tēnā koutou katoa.

As we are in a period of capital raising, it is important we update you with the latest sales information as you consider the pro-rata rights offer.

With only 3 weeks of sales in November, we are experiencing record months in both New Zealand and Australia. With an additional week of sales remaining, this will only further this increase.

==> picture [432 x 253] intentionally omitted <==

----- Start of picture text ----- Unit sales by Country2000160012008004000D-23 J-24 F-24 M-24 A-24 M-24 J-24 J-24 A-24 S-24 0-24 N-24to dateAustralia New Zealand Germany----- End of picture text -----

Record month and new products in New Zealand

Sales in New Zealand have grown month-on-month, culminating in a record month for Rua with unit sales in November 2024 greater than all previous months. As a recent entrant to the NZ market with dried flower inhalation product this is a clear reflection of the trust placed in Rua in our home market.

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com

This is expected to grow further as we bring additional products to the market. In early December we will be launching a new product which will be available to Doctors and Pharmacists. It will be our second flower product, featuring the highest potency approved for sale in New Zealand. This milestone is one that we are immensely proud of, and we expect the product to be very well received in the market.

Australia now growing strongly

Rua is experiencing a record-breaking month for November in Australia also. More units of Rua products were sold this month than in any other previous period and we still have one week of sales remaining. This result is a testament to our diverse portfolio, strategic market positioning and solid relationships with key stakeholders in the market. These relationships are translating into repeat sales, reinforcing our long-term growth trajectory.

Demand exceeds supply in Germany

We are experiencing regular, repeat orders in Germany but demand for our product exceeds our supply. Despite this we have developed a strong base of demand and will build on this as new product is delivered.

New premium product will be launched the first week of December. This is our largest consignment purchased for Germany and we expect sales to continue to grow.

Products now in the United Kingdom

Our first portfolio of products have arrived in the UK this week and are clearing customs. We expect these products to be available for prescription in the UK market early December. We have been communicating with key clinics in the market ahead of the launch and we expect greater market penetration in Q4 FY25.

Portfolio of countries

Achieving revenue in three countries, and soon to be four with the addition of the UK in December, is a huge success for the company and creates robust and resilient revenue. It is further evidence of Rua’s ability to execute on its strategic plan of taken unique legacy genetics to key export and domestic markets.

ENDS

The person who authorised this announcement:

Paul Naske Chief Executive Officer paul.naske@ruabio.com +64 21 445154

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com